|
1
|
Gatta G, Faivre J, Capocaccia R and Ponz
de Leon M: Survival of colorectal cancer patients in Europe during
the period 1978–1989. Eur J Cancer. 34:2176–2183. 1998.
|
|
2
|
Grothey A, Sargent D, Goldberg RM and
Schmoll HJ: Survival of patients with advanced colorectal cancer
improves with the availability of fluorouracil-leucovorin,
irinotecan, and oxaliplatin in the course of treatment. J Clin
Oncol. 22:1209–1214. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kelly H and Goldberg RM: Systemic therapy
for metastatic colorectal cancer: current options, current
evidence. J Clin Oncol. 23:4553–4560. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ho C, Ng K, O’Reilly S and Gill S:
Outcomes in elderly patients with advanced colorectal cancer
treated with capecitabine: a population-based analysis. Clin
Colorectal Cancer. 5:279–282. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferrucci L, Guralnik JM, Cavazzini C,
Bandinelli S, Lauretani F, Bartali B, Repetto L and Longo DL: The
frailty syndrome: a critical issue in geriatric oncology. Crit Rev
Oncol Hematol. 46:127–137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Walston J, Hadley EC, Ferrucci L, Guralnik
JM, Newman AB, Studenski SA, Ershler WB, Harris T and Fried LP:
Research agenda for frailty in older adults: toward a better
understanding of physiology and etiology: summary from the American
Geriatrics Society/National Institute on Aging Research Conference
on frailty in older adults. J Am Geriatr Soc. 54:991–1001. 2006.
View Article : Google Scholar
|
|
7
|
Sawhney R, Sehl M and Naeim A: Physiologic
aspects of aging: impact on cancer management and decision making,
part I. Cancer J. 11:449–460. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sehl M, Sawhney R and Naeim A: Physiologic
aspects of aging: impact on cancer management and decision making,
part II. Cancer J. 11:461–473. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Given B, Given C, Azzouz F and Stommel M:
Physical functioning of elderly cancer patients prior to diagnosis
and following initial treatment. Nurs Res. 50:222–232. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sargent DJ, Goldberg RM, Jacobson SD,
Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF and
Francini G: A pooled analysis of adjuvant chemotherapy for resected
colon cancer in elderly patients. N Engl J Med. 345:1091–1097.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goldberg RM, Tabah-Fisch I, Bleiberg H, de
Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E and
Sargent DJ: Pooled analysis of safety and efficacy of oxaliplatin
plus fluorouracil/leucovorin administered bimonthly in elderly
patients with colorectal cancer. J Clin Oncol. 24:4085–4091. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sastre J, Marcuello E, Masutti B, Navarro
M, Gil S, Antón A, Abad A, Aranda E, Maurel J, Valladares M, Maestu
I, Carrato A, Vicent JM and Díaz-Rubio E; Cooperative Group for the
Treatment of Digestive Tumors. Irinotecan in combination with
fluorouracil in a 48-hour continuous infusion as first-line
chemotherapy for elderly patients with metastatic colorectal
cancer: a Spanish Cooperative Group for the Treatment of Digestive
Tumors study. J Clin Oncol. 23:3545–3551. 2005. View Article : Google Scholar
|
|
13
|
Souglakos J, Pallis A, Kakolyris S,
Mavroudis D, Androulakis N, Kouroussis C, Agelaki S, Xenidis N,
Milaki G and Georgoulias V: Combination of irinotecan (CPT-11) plus
5-fluorouracil and leucovorin (FOLFIRI regimen) as first line
treatment for elderly patients with metastatic colorectal cancer: a
phase II trial. Oncology. 69:384–390. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fuchs CS, Moore MR, Harker G, Villa L,
Rinaldi D and Hecht JR: Phase III comparison of two irinotecan
dosing regimens in second-line therapy of metastatic colorectal
cancer. J Clin Oncol. 21:807–814. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar
|
|
16
|
Cunningham D, Pyrhönen S, James RD, Punt
CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham
CA, Awad L, Jacques C and Herait P: Randomised trial of irinotecan
plus supportive care versus supportive care alone after
fluorouracil failure for patients with metastatic colorectal
cancer. Lancet. 352:1413–1418. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Folprecht G, Seymour MT, Saltz L,
Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E,
Rougier P, Mitry E, Schubert U and Köhne CH:
Irinotecan/fluorouracil combination in first-line therapy of older
and younger patients with metastatic colorectal cancer: combined
analysis of 2.691 patients in randomized controlled trials. J Clin
Oncol. 26:1443–1451. 2008. View Article : Google Scholar
|
|
18
|
Feliu J, Salud A, Escudero P, Lopez-Gómez
L, Bolanos M, Galán A, Vicent JM, Yubero A, Losa F, De Castro J, de
Mon MA, Casado E and González-Barón M: XELOX (capecitabine plus
oxaliplatin) as first-line treatment for elderly patients over 70
years of age with advanced colorectal cancer. Br J Cancer.
94:969–975. 2006.PubMed/NCBI
|
|
19
|
Au HJ, Mulder KE and Fields AL: Systematic
review of management of colorectal cancer in elderly patients. Clin
Colorectal Cancer. 3:165–171. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G,
Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by
FOLFOX6 or the reverse sequence in advanced colorectal cancer: a
randomized GERCOR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Balducci L and Extermann M: Management of
cancer in the older person: a practical approach. Oncologist.
5:224–237. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Macdonald JS: Vive la difference: gender
and fluorouracil toxicity. J Clin Oncol. 20:1439–1341. 2002.
|
|
23
|
Sobrero AF, Maurel J, Fehrenbacher L,
Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C,
Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H,
Luppi G, Kisker O, Zubel A, Langer C, Kopit J and Burris HA III:
EPIC: phase III trial of cetuximab plus irinotecan after
fluoropyrimidine and oxaliplatin failure in patients with
metastatic colorectal cancer. J Clin Oncol. 26:2311–2319. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chau I, Norman AR, Cunningham D, Waters
JS, Topham C, Middleton G, Hill M, Ross PJ, Katopodis R, Stewart G
and Oates JR: Elderly patients with fluoropyrimidine and
thymidylate synthase inhibitor-resistant advanced colorectal cancer
derive similar benefit without excessive toxicity when treated with
irinotecan monotherapy. Br J Cancer. 91:1453–1458. 2004. View Article : Google Scholar
|
|
25
|
Bouchahda M, Macarulla T, Spano JP, Bachet
JB, Lledo G, Andre T, Landi B, Tabernero J, Karaboué A, Domont J,
Levi F and Rougier P: Cetuximab efficacy and safety in a
retrospective cohort of elderly patients with heavily pretreated
metastatic colorectal cancer. Crit Rev Oncol Hematol. 67:255–262.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iyer L, Das S, Janisch L, Wen M, Ramírez
J, Karrison T, Fleming GF, Vokes EE, Schilsky RL and Ratain MJ:
UGT1A1*28 polymorphism as a determinant of irinotecan
disposition and toxicity. Pharmacogenomics J. 2:43–47. 2002.
|
|
27
|
Innocenti F, Undevia SD, Iyer L, Chen PX,
Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM,
Vokes EE and Ratain MJ: Genetic variants in the
UDP-glucuronosyltransferase 1A1 gene predict the risk of severe
neutropenia of irinotecan. J Clin Oncol. 22:1382–1388. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Toffoli G, Cecchin E, Corona G, Russo A,
Buonadonna A, D’Andrea M, Pasetto LM, Pessa S, Errante D, De
Pangher V, Giusto M, Medici M, Gaion F, Sandri P, Galligioni E,
Bonura S, Boccalon M, Biason P and Frustaci S: The role of
UGT1A1*28 polymorphism in the pharmacodynamics and
pharmacokinetics of irinotecan in patients with metastatic
colorectal cancer. J Clin Oncol. 24:3061–3068. 2006.PubMed/NCBI
|
|
29
|
Ruzzo A, Graziano F, Loupakis F, Santini
D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F,
Falcone A, Canestrari E, Tonini G, Mari D, Lippe P, Pizzagalli F,
Schiavon G, Alessandroni P, Giustini L, Maltese P, Testa E,
Menichetti ET and Magnani M: Pharmacogenetic profiling in patients
with advanced colorectal cancer treated with first-line FOLFIRI
chemotherapy. Pharmacogenomics J. 8:278–288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cecchin E, Innocenti F, D’Andrea M, Corona
G, De Mattia E, Biason P, Buonadonna A and Toffoli G: Predictive
role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their
haplotypes on the outcome of metastatic colorectal cancer patients
treated with fluorouracil, leucovorin, and irinotecan. J Clin
Oncol. 27:457–465. 2009. View Article : Google Scholar
|
